Novo Nordisk A/S (NVO) Shares are Up 0.02%

Novo Nordisk A/S (NVO) has been under a strong bear grip, hence the stock is down -17.52% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 0.68% in the past 1 week. The stock has risen by 0.02% in the past week indicating that the buyers are active at lower levels, but the stock is down -17.69% in the past 4 weeks.

Company shares have received an average consensus rating of Hold for the current week The stock has recorded a twenty day Moving Average of 4.74% and the fifty day Moving Average is 9.51%. Novo Nordisk A/S has dropped 14.61% during the last three month period . Year-to-Date the stock performance stands at -17.05%.


Novo Nordisk A/S (NYSE:NVO): stock turned positive on Friday. Though the stock opened at $46.88, the bulls momentum made the stock top out at $47.18 level for the day. The stock recorded a low of $46.62 and closed the trading day at $46.89, in the green by 0.09%. The total traded volume for the day was 1,600,893. The stock had closed at $46.85 in the previous days trading.

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It has a range of diabetes product portfolio, including a portfolio of modern insulins as well as a human once-daily GLP-1 analog. It operates in two segments: diabetes care and biopharmaceuticals. The Companys diabetes care segment covers insulins, GLP-1, other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. Its biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy and hormone replacement therapy. The primary production facilities owned by the Company are located at a number of sites in Denmark, and internationally in the United States, France, China and Brazil.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.